IQVIA Holdings Inc. $IQV Shares Sold by Pinnbrook Capital Management LP

Pinnbrook Capital Management LP lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 47.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,444 shares of the medical research company’s stock after selling 11,925 shares during the quarter. Pinnbrook Capital Management LP’s holdings in IQVIA were worth $3,030,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IQV. Brighton Jones LLC boosted its holdings in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at $514,000. First Trust Advisors LP boosted its holdings in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $167.87 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market capitalization of $28.02 billion, a P/E ratio of 20.80, a P/E/G ratio of 1.64 and a beta of 1.18. The company’s fifty day moving average price is $169.78 and its two-hundred day moving average price is $197.77.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the business posted $2.70 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. Citigroup reduced their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Finally, Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Buy” and an average price target of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.